Revised interim results can be found here and are as stated below.

Highlights

• Revenue up 17% to £5.1 million (2018: £4.4 million)
• Profit before tax up 26% to £4.1 million (2018: £3.2 million)
• Closing cash balances unchanged at £5.5 million
• First interim dividend up 20% to 36p per share (2018: 30p)

(more…)

Bioventix plc
(“Bioventix” or the “Company”)

Issue of Equity

(more…)

(more…)

Bioventix plc
(“Bioventix” or the “Company”)
Result of AGM

Bioventix plc (AIM: BVXP) announces that at its Annual General Meeting (“AGM”), all resolutions put to shareholders were duly passed.

(more…)

(more…)

Director’s report and financial statements for the year ended 30th June 2019.
To download this report as a PDF file click here.

Bioventix plc (BVXP) was notified on 25 October 2019 of the following transaction in its ordinary shares of 5 pence each (“Ordinary Shares”). (more…)

Bioventix plc (BVXP) announces its audited results for the year ended 30 June 2019. (more…)

TR-1: Notification of major interest in shares. To download this report as a PDF file click here.

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces that it will release its preliminary results for the year ended 30 June 2019 on 21 October 2019.

(more…)